Abstract
The prevalence of adrenal incidentaloma has increased with the increasing use of imaging techniques. While majority are benign adenoma, a small but significant minority may be primary adrenal carcinoma or have endocrine hyper secretion. Existing guidance suggests that excess catecholamine and cortisol secretion should be ruled out in all cases and excess aldosterone secretion should be ruled out in hypertensive patients. Repeat evaluation after a period of time is also suggested. We have reviewed the management of adrenal incidentaloma in a large district general hospital in the North West of England.
References
G. Mansmann et al., The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev. 25(2), 309–340 (2004)
L. Hammarstedt et al., Adrenal Study Group of Western Sweden. Adrenal lesion frequency: a prospective, cross-sectional CT study in a defined region, including systematic re-evaluation. Acta Radiol. 51(10), 1149–1156 (2010)
T.J. Cawood et al., Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur. J. Endocrinol. 161(4), 513–527 (2009)
W.F. Young Jr., The incidentally discovered adrenal mass. N. Engl. J. Med. 356, 601–610 (2007)
I. Chiodini et al., Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J. Clin. Endocrinol. Metab. 95(6), 2736–2745 (2010)
NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”). NIH Consens. State Sci. Statements. 19(2), 1–25 (2002)
American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations
M.A. Zeiger et al., American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations. Endocr Pract 15(5), 450–453 (2009)
L.K. Nieman, Approach to the patient with an adrenal incidentaloma. J. Clin. Endocrinol. Metab. 95(9), 4106–4113 (2010)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bujawansa, S., Bowen-Jones, D. Low investigation rate for adrenal incidentalomas. Endocrine 40, 134–136 (2011). https://doi.org/10.1007/s12020-011-9487-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-011-9487-9